VERA (Vera Therapeutics) Long-Term Debt: $75.03 Mil (As of Mar. 2026)


VERA Vera Therapeutics Inc VERA
34 GF Score
Price $42.00
! 3 Warning Signs
View Full Analysis

What is Vera Therapeutics Long-Term Debt?

Vera Therapeutics VERA -1.06% 34 Long-Term Debt is $75.03 Mil as of Mar. 2026. GuruFocus rates VERA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Vera Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $75.03 Mil.

Vera Therapeutics's quarterly Long-Term Debt increased from Sep. 2025 ($74.65 Mil) to Dec. 2025 ($74.84 Mil) and increased from Dec. 2025 ($74.84 Mil) to Mar. 2026 ($75.03 Mil).

Vera Therapeutics's annual Long-Term Debt increased from Dec. 2023 ($49.88 Mil) to Dec. 2024 ($50.69 Mil) and increased from Dec. 2024 ($50.69 Mil) to Dec. 2025 ($74.84 Mil).

Vera Therapeutics  (NAS:VERA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Vera Therapeutics Long-Term Debt Related Terms

Vera Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Vera Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vera Therapeutics Long-Term Debt Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 4.92 24.81 49.88 50.69 74.84

Vera Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.91 74.46 74.65 74.84 75.03
VERA
34GF Score
Vera Therapeutics Inc VERA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $75.03 Mil mean?
Vera Therapeutics (VERA) has a Long-Term Debt of $75.03 Mil as of Mar. 2026.
Is Vera Therapeutics' Long-Term Debt too high?
Vera Therapeutics' current Long-Term Debt is $75.03 Mil. Overall, Vera Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Vera Therapeutics' Long-Term Debt compare to RARE and IRON?
Vera Therapeutics' Long-Term Debt of $75.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Vera Therapeutics's current Long-Term Debt is $75.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vera Therapeutics stock overvalued right now?
Vera Therapeutics (VERA) has a current Long-Term Debt of $75.03 Mil. The current Long-Term Debt is $75.03 Mil. Vera Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Vera Therapeutics (VERA), the current Long-Term Debt is $75.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vera Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 1200, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
34GF Score

Get the complete analysis for VERA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.00
Price